Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors Article Swipe
Geoffrey I. Shapiro
,
Jordi Rodón
,
Cynthia Bedell
,
Eunice L. Kwak
,
José Baselga
,
Irene Braña
,
Shuchi S. Pandya
,
Christian Scheffold
,
Alexander Laird
,
Linh T. Nguyen
,
Yi Xu
,
Coumaran Égile
,
Gerald M. Edelman
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.22448123
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1078-0432.22448123
PDF file - 63K, Reduction of PI3K pathway signaling in serial hair samples and skin biopsies.
Related Topics
Concepts
Metadata
- Type
- supplementary-materials
- Language
- en
- Landing Page
- https://doi.org/10.1158/1078-0432.22448123
- https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_2_from_Phase_I_Safety_Pharmacokinetic_and_Pharmacodynamic_Study_of_SAR245408_XL147_an_Oral_Pan-Class_I_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors/22448123/1/files/39899168.pdf
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4361882140
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4361882140Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1078-0432.22448123Digital Object Identifier
- Title
-
Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid TumorsWork title
- Type
-
supplementary-materialsOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-03-31Full publication date if available
- Authors
-
Geoffrey I. Shapiro, Jordi Rodón, Cynthia Bedell, Eunice L. Kwak, José Baselga, Irene Braña, Shuchi S. Pandya, Christian Scheffold, Alexander Laird, Linh T. Nguyen, Yi Xu, Coumaran Égile, Gerald M. EdelmanList of authors in order
- Landing page
-
https://doi.org/10.1158/1078-0432.22448123Publisher landing page
- PDF URL
-
https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_2_from_Phase_I_Safety_Pharmacokinetic_and_Pharmacodynamic_Study_of_SAR245408_XL147_an_Oral_Pan-Class_I_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors/22448123/1/files/39899168.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_2_from_Phase_I_Safety_Pharmacokinetic_and_Pharmacodynamic_Study_of_SAR245408_XL147_an_Oral_Pan-Class_I_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors/22448123/1/files/39899168.pdfDirect OA link when available
- Concepts
-
Pharmacodynamics, Pharmacokinetics, PI3K/AKT/mTOR pathway, Class (philosophy), Pharmacology, Table (database), Phase (matter), Medicine, Internal medicine, Chemistry, Computer science, Signal transduction, Biochemistry, Artificial intelligence, Data mining, Organic chemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4361882140 |
|---|---|
| doi | https://doi.org/10.1158/1078-0432.22448123 |
| ids.doi | https://doi.org/10.1158/1078-0432.22448123 |
| ids.openalex | https://openalex.org/W4361882140 |
| fwci | 0.0 |
| type | supplementary-materials |
| title | Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T11811 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9932000041007996 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2708 |
| topics[0].subfield.display_name | Dermatology |
| topics[0].display_name | Cutaneous lymphoproliferative disorders research |
| topics[1].id | https://openalex.org/T11157 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9485999941825867 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2716 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Chronic Lymphocytic Leukemia Research |
| topics[2].id | https://openalex.org/T11491 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9067000150680542 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | CAR-T cell therapy research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C111113717 |
| concepts[0].level | 3 |
| concepts[0].score | 0.6657631397247314 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q725307 |
| concepts[0].display_name | Pharmacodynamics |
| concepts[1].id | https://openalex.org/C112705442 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6272655725479126 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q323936 |
| concepts[1].display_name | Pharmacokinetics |
| concepts[2].id | https://openalex.org/C86554907 |
| concepts[2].level | 3 |
| concepts[2].score | 0.5391882061958313 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q285613 |
| concepts[2].display_name | PI3K/AKT/mTOR pathway |
| concepts[3].id | https://openalex.org/C2777212361 |
| concepts[3].level | 2 |
| concepts[3].score | 0.4783158600330353 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q5127848 |
| concepts[3].display_name | Class (philosophy) |
| concepts[4].id | https://openalex.org/C98274493 |
| concepts[4].level | 1 |
| concepts[4].score | 0.47452202439308167 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[4].display_name | Pharmacology |
| concepts[5].id | https://openalex.org/C45235069 |
| concepts[5].level | 2 |
| concepts[5].score | 0.4289293885231018 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q278425 |
| concepts[5].display_name | Table (database) |
| concepts[6].id | https://openalex.org/C44280652 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4256651699542999 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q104837 |
| concepts[6].display_name | Phase (matter) |
| concepts[7].id | https://openalex.org/C71924100 |
| concepts[7].level | 0 |
| concepts[7].score | 0.395441472530365 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[7].display_name | Medicine |
| concepts[8].id | https://openalex.org/C126322002 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3618885278701782 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[8].display_name | Internal medicine |
| concepts[9].id | https://openalex.org/C185592680 |
| concepts[9].level | 0 |
| concepts[9].score | 0.3537418842315674 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[9].display_name | Chemistry |
| concepts[10].id | https://openalex.org/C41008148 |
| concepts[10].level | 0 |
| concepts[10].score | 0.21472665667533875 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[10].display_name | Computer science |
| concepts[11].id | https://openalex.org/C62478195 |
| concepts[11].level | 2 |
| concepts[11].score | 0.1528107225894928 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q828130 |
| concepts[11].display_name | Signal transduction |
| concepts[12].id | https://openalex.org/C55493867 |
| concepts[12].level | 1 |
| concepts[12].score | 0.13118091225624084 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[12].display_name | Biochemistry |
| concepts[13].id | https://openalex.org/C154945302 |
| concepts[13].level | 1 |
| concepts[13].score | 0.09745252132415771 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q11660 |
| concepts[13].display_name | Artificial intelligence |
| concepts[14].id | https://openalex.org/C124101348 |
| concepts[14].level | 1 |
| concepts[14].score | 0.07409927248954773 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q172491 |
| concepts[14].display_name | Data mining |
| concepts[15].id | https://openalex.org/C178790620 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q11351 |
| concepts[15].display_name | Organic chemistry |
| keywords[0].id | https://openalex.org/keywords/pharmacodynamics |
| keywords[0].score | 0.6657631397247314 |
| keywords[0].display_name | Pharmacodynamics |
| keywords[1].id | https://openalex.org/keywords/pharmacokinetics |
| keywords[1].score | 0.6272655725479126 |
| keywords[1].display_name | Pharmacokinetics |
| keywords[2].id | https://openalex.org/keywords/pi3k/akt/mtor-pathway |
| keywords[2].score | 0.5391882061958313 |
| keywords[2].display_name | PI3K/AKT/mTOR pathway |
| keywords[3].id | https://openalex.org/keywords/class |
| keywords[3].score | 0.4783158600330353 |
| keywords[3].display_name | Class (philosophy) |
| keywords[4].id | https://openalex.org/keywords/pharmacology |
| keywords[4].score | 0.47452202439308167 |
| keywords[4].display_name | Pharmacology |
| keywords[5].id | https://openalex.org/keywords/table |
| keywords[5].score | 0.4289293885231018 |
| keywords[5].display_name | Table (database) |
| keywords[6].id | https://openalex.org/keywords/phase |
| keywords[6].score | 0.4256651699542999 |
| keywords[6].display_name | Phase (matter) |
| keywords[7].id | https://openalex.org/keywords/medicine |
| keywords[7].score | 0.395441472530365 |
| keywords[7].display_name | Medicine |
| keywords[8].id | https://openalex.org/keywords/internal-medicine |
| keywords[8].score | 0.3618885278701782 |
| keywords[8].display_name | Internal medicine |
| keywords[9].id | https://openalex.org/keywords/chemistry |
| keywords[9].score | 0.3537418842315674 |
| keywords[9].display_name | Chemistry |
| keywords[10].id | https://openalex.org/keywords/computer-science |
| keywords[10].score | 0.21472665667533875 |
| keywords[10].display_name | Computer science |
| keywords[11].id | https://openalex.org/keywords/signal-transduction |
| keywords[11].score | 0.1528107225894928 |
| keywords[11].display_name | Signal transduction |
| keywords[12].id | https://openalex.org/keywords/biochemistry |
| keywords[12].score | 0.13118091225624084 |
| keywords[12].display_name | Biochemistry |
| keywords[13].id | https://openalex.org/keywords/artificial-intelligence |
| keywords[13].score | 0.09745252132415771 |
| keywords[13].display_name | Artificial intelligence |
| keywords[14].id | https://openalex.org/keywords/data-mining |
| keywords[14].score | 0.07409927248954773 |
| keywords[14].display_name | Data mining |
| language | en |
| locations[0].id | doi:10.1158/1078-0432.22448123 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_2_from_Phase_I_Safety_Pharmacokinetic_and_Pharmacodynamic_Study_of_SAR245408_XL147_an_Oral_Pan-Class_I_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors/22448123/1/files/39899168.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1078-0432.22448123 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5045419282 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3331-4095 |
| authorships[0].author.display_name | Geoffrey I. Shapiro |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Geoffrey I. Shapiro |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5031165814 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6467-3632 |
| authorships[1].author.display_name | Jordi Rodón |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Jordi Rodon |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5110193751 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Cynthia Bedell |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Cynthia Bedell |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5108626576 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Eunice L. Kwak |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Eunice L. Kwak |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5004300577 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-1361-4063 |
| authorships[4].author.display_name | José Baselga |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jose Baselga |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5079422406 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-1068-9601 |
| authorships[5].author.display_name | Irene Braña |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Irene Braña |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5112105224 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Shuchi S. Pandya |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Shuchi S. Pandya |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5103600408 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Christian Scheffold |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Christian Scheffold |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5087379820 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-7296-025X |
| authorships[8].author.display_name | Alexander Laird |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | A. Douglas Laird |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5106428542 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-4143-5225 |
| authorships[9].author.display_name | Linh T. Nguyen |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Linh T. Nguyen |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5100419183 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-5768-8235 |
| authorships[10].author.display_name | Yi Xu |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Yi Xu |
| authorships[10].is_corresponding | False |
| authorships[11].author.id | https://openalex.org/A5032887436 |
| authorships[11].author.orcid | |
| authorships[11].author.display_name | Coumaran Égile |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Coumaran Egile |
| authorships[11].is_corresponding | False |
| authorships[12].author.id | https://openalex.org/A5111917213 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Gerald M. Edelman |
| authorships[12].author_position | last |
| authorships[12].raw_author_name | Gerald Edelman |
| authorships[12].is_corresponding | False |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_2_from_Phase_I_Safety_Pharmacokinetic_and_Pharmacodynamic_Study_of_SAR245408_XL147_an_Oral_Pan-Class_I_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors/22448123/1/files/39899168.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11811 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9932000041007996 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2708 |
| primary_topic.subfield.display_name | Dermatology |
| primary_topic.display_name | Cutaneous lymphoproliferative disorders research |
| related_works | https://openalex.org/W2352350815, https://openalex.org/W2991030316, https://openalex.org/W2908757458, https://openalex.org/W2887865523, https://openalex.org/W2112528869, https://openalex.org/W2189230703, https://openalex.org/W2114878163, https://openalex.org/W2162888433, https://openalex.org/W2254638634, https://openalex.org/W2369345461 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1078-0432.22448123 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_2_from_Phase_I_Safety_Pharmacokinetic_and_Pharmacodynamic_Study_of_SAR245408_XL147_an_Oral_Pan-Class_I_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors/22448123/1/files/39899168.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1078-0432.22448123 |
| primary_location.id | doi:10.1158/1078-0432.22448123 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://aacr.figshare.com/articles/journal_contribution/Supplementary_Table_2_from_Phase_I_Safety_Pharmacokinetic_and_Pharmacodynamic_Study_of_SAR245408_XL147_an_Oral_Pan-Class_I_PI3K_Inhibitor_in_Patients_with_Advanced_Solid_Tumors/22448123/1/files/39899168.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1078-0432.22448123 |
| publication_date | 2023-03-31 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.- | 2 |
| abstract_inverted_index.in | 9 |
| abstract_inverted_index.of | 5 |
| abstract_inverted_index.and | 13 |
| abstract_inverted_index.63K, | 3 |
| abstract_inverted_index.PI3K | 6 |
| abstract_inverted_index.file | 1 |
| abstract_inverted_index.hair | 11 |
| abstract_inverted_index.skin | 14 |
| abstract_inverted_index.serial | 10 |
| abstract_inverted_index.pathway | 7 |
| abstract_inverted_index.samples | 12 |
| abstract_inverted_index.Reduction | 4 |
| abstract_inverted_index.signaling | 8 |
| abstract_inverted_index.<p>PDF | 0 |
| abstract_inverted_index.biopsies.</p> | 15 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 13 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.4099999964237213 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.08328265 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |